Five Hurdles for Biotech
Five Hurdles for Biotech
The science is hot and the stocks are up. Here’s what’s needed to deliver on the promise.
Puncturing The ImClone Hype
Puncturing The ImClone Hype
Could ImClone Systems’ Erbitux be a powerful cancer fighter after all? Maybe.
A new study presented June 1 at a meeting of oncologists seems to boost that contention. But there are still reasons to doubt that Erbitux will be approved soon or that it will eventually be a blockbuster.
China's Killer Headache: Fake Pharmaceuticals
China’s Killer Headache: Fake Pharmaceuticals
An estimated 192,000 people died last year in China because of fake drugs, according to the Shenzhen Evening News, a government-controlled newspaper. Some die from toxins in counterfeit medicines, and others from infection because they are swallowing bogus pills instead of antibiotics
Looking beyond Patent Expiry
Looking beyond Patent Expiry
The problem of patent protection loss and associated revenue loss will continue to trouble major companies, with estimated revenue losses of US$2.2 billion in 2004 from patent expiries on 18 drugs, increasing to an estimated US$5.3 billion in 2005.
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments